SuperworthSpyre Therapeutics revenue SYRE
Sales by quarter and over the last twelve months, from 2017.
- Last 12 months, to Dec 31, 2024
- $0
- Latest quarter, Q4 FY24
- $0
- Fiscal year 2024
- $0
- −100% on the year before
Spyre Therapeutics' revenue was $0 over the twelve months to Dec 31, 2024, down 100% on a year earlier.
In its latest quarter, Q4 FY24, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2024 | $0 | −100% |
| FY2023 | $886K | −62% |
| FY2022 | $2.3M | −88% |
| FY2021 | $18.7M | n/a |
| FY2019 | $0 | −100% |
| FY2018 | $3.9M | −25% |
| FY2017 | $5.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY24 | $0 | n/a | $0 | |
| Q3 FY24 | $0 | n/a | $0 | |
| Q2 FY24 | $0 | −100% | $0 | |
| Q1 FY24 | $0 | −100% | $688K | |
| Q4 FY23 | $0 | −100% | $886K | |
| Q3 FY23 | $0 | −100% | $1.1M | |
| Q2 FY23 | $688K | +10% | $1.2M | |
| Q1 FY23 | $198K | −85% | $1.2M | |
| Q4 FY22 | $168K | −95% | $2.3M | |
| Q3 FY22 | $174K | −88% | $5.8M | |
| Q2 FY22 | $625K | −95% | $7M | |
| Q1 FY22 | $1.4M | n/a | $20.1M |
Against its peers
Companies in Drug Manufacturers - General nearest Spyre Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| SYRESpyre Therapeutics | n/m | |
| TGTXTG Therapeutics | $799.5M | +76% a year |
| ALKSAlkermes plc. | $1.7B | +11% a year |
| PTGXProtagonist Therapeutics | $282M | +35% a year |
| CORTCorcept Therapeutics | $830.8M | +16% a year |
| AMRXAmneal Pharmaceuticals | $3.1B | +9% a year |
| LGNDLigand Pharmaceuticals | $290.5M | +55% a year |
| KNSAKiniksa Pharmaceuticals International | $840.8M | +59% a year |
| BMRNBiomarin Pharmaceutical | $3.4B | +11% a year |
| JAZZJazz Pharmaceuticals | $4.6B | +13% a year |
| INDVIndivior Pharmaceuticals | $1.3B | +13% a year |
| Peer median | $1.1B |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Spyre Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.